Skip to main content

Table 8 Important pharmacokinetic parameters for bioavailability of compounds 4a, 7a, 7b, 7c, 9c, 15b, 16a, 16b and 16c

From: Synthesis, anticancer evaluation, molecular docking and ADME study of novel pyrido[4ʹ,3ʹ:3,4]pyrazolo[1,5-a]pyrimidines as potential tropomyosin receptor kinase A (TrKA) inhibitors

Compd. no

M. Wt

g/mol

LogP

TPSA

GI abs

HBA

HBD

nRotb

Violations

4a

230.22

0.63

76.36 Ǻ2

high

4

1

0

0

7a

318.33

2.21

76.36 Ǻ2

high

4

1

0

0

7b

348.36

2.22

85.59 Ǻ2

high

5

1

2

0

7c

352.77

2.78

76.36 Ǻ2

high

4

1

1

0

9c

364.36

1.88

113.74 Ǻ2

high

6

2

3

0

15b

350.33

1.68

105.82 Ǻ2

high

6

2

2

0

16a

336.30

1.34

124.74 Ǻ2

high

6

3

2

0

16b

350.33

1.67

124.74 Ǻ2

high

6

3

2

0

16c

366.33

1.30

133.97 Ǻ2

high

7

3

3

0

Back to article page

BMC Chemistry

ISSN: 2661-801X

Contact us